not used title

not used title

President Trump has called on U.S. industries to put America first, and the biopharmaceutical sector is answering that call with major actions to demonstrate our commitment to American patients and workers. 

Historic investments are underway across America.  
PhRMA member companies are delivering $500 billion in new U.S.-based manufacturing and infrastructure investment, injecting an estimated $1.2 trillion into the economy. For every $1 invested by our industry, another $1.60 is spent in other areas of the economy, creating a ripple effect. These investments will create more than 100,000 jobs - including 25,000 biopharma facility jobs - seizing on President Trump’s tax law changes and regulatory streamlining that make it more attractive to invest in the U.S.

The biopharmaceutical industry steps up for patients – every year. 
Too many Americans struggle to afford their medicine because of a broken health insurance system that burdens patients with increasing out-of-pocket costs and coverage denials. Through company support programs, 10 million patients receive financial assistance from biopharmaceutical companies annually. At the same time, research shows over 1,400 medicines were excluded from commercials formularies in 2025 alone and this number has grown over the years with PBMs excluding an average of 27% more medicines each year.

• Zoom in: This includes a 164% increase in generics and biosimilars being excluded since 2022.

Connecting Americans with more convenient access to medicines.
Launching in January 2026, PhRMA plans to build a search engine that will point patients to prescription medicine direct purchase programs (DPPs), independently set up by biopharmaceutical manufacturing companies. AmericasMedicines.com will connect patients to DPPs where they can buy prescriptions directly from manufacturers as well as search the site’s 750+ patient assistance resources. While pharmaceutical manufacturers must make their own decisions to offer DPP, this new website will allow manufacturers to list a wide range of medicines and connect patients directly to available options. 

But American patients will pay the price for bad policies if more is not done.
Proposals like most favored nation price controls and tariffs will undermine American leadership of the biopharmaceutical industry and limit treatment availability for patients. Europe continues to undervalue medical innovation. The U.K.’s own science minister acknowledged, “The tradeoff that’s been made for the past decade is a lower percentage on medicines, and we’re reaping the consequences of that now in a very urgent way.”  Meanwhile, middlemen and others here at home pocket half of every dollar spent on brand medicines. These imbalances drive up costs for everyone. 

The bottom line: Biopharmaceutical companies are doing our part to protect American patients and workers.
The biopharmaceutical industry is stepping up with new innovative cures, infrastructure investments, new jobs, as well as patient resources. However, to reduce price differentials with other wealthy countries, we should require PBMs to share savings directly with patients and reform misaligned incentives, fix the 340B hospital markup program, and force foreign governments to pay their fair share for cutting-edge innovation.

Learn more at AmericasMedicines.com.

Stephen J. Ubl

Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America.

Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics."

Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.

Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).

He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.

https://x.com/steveubl

https://www.linkedin.com/in/steveubl/

President and Chief Executive Officer

ICYMI: Pennsylvania shows what biopharmaceutical innovation can deliver

September 21, 2026

New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums

September 18, 2026

What AARP isn’t telling seniors about MFN

August 24, 2026

Policymakers should improve patient access and reject price controls

August 18, 2026

Insurers blame GLP-1s for rising costs. The data tells a different story.

August 14, 2026

The FTC’s PBM enforcement actions gave us a glimpse behind the curtain; it’s time to let the light in.

August 7, 2026

Nearly 1 in 4 patients initially denied access to IRA medicines

August 6, 2026

Message to USAging: Providers are raising concerns about coverage barriers

July 22, 2026

New PBM principles don't change the fundamental challenge: Access to lower-cost medicines

July 10, 2026

Staffing up: Building the future biopharma workforce to keep America in the lead

June 29, 2026

340B’s reality: A booming business for hospitals, pharmacies and corporate giants

June 25, 2026

Insurers are blaming medicines for premium hikes in Massachusetts. The state's own data suggests otherwise.

June 24, 2026

Nearly 80 researchers advocate on Capitol Hill

June 11, 2026

MFN price controls threaten American jobs and the U.S. economy

May 28, 2026

Briefing: Capitol Hill panel on "Healthcare Denial Crisis in America"

April 24, 2026

Survey confirms too many insured Americans face barriers to reliable health care

April 22, 2026

70% DENIED: How insurance denials are delaying and preventing care for millions of Americans

April 14, 2026

Hospitals drive nearly 80% of the U.S. health spending gap

March 25, 2026

No hassle, hidden markups or fees: AmericasMedicines.com

February 19, 2026

America Cures: Championing U.S. leadership in medical innovation

February 18, 2026

The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses

February 17, 2026

Separating fact from fiction in the medicine supply chain

February 11, 2026

Congratulations to our 2026 Working for Cures Employee Champions

January 29, 2026

50-state poll says Americans are concerned that hospital markups hurt patients

January 27, 2026

Three things you should know from the insurer CEO congressional hearings

January 26, 2026

Can’t get your medicine? Don’t count on your insurer.

January 15, 2026

Stop, collaborate and re-evaluate: ICER’s pricing report

November 14, 2025

California’s landmark PBM crackdown: A wake-up call for reform

November 13, 2025

Middlemen mark up drug prices and keep discounts meant for you

November 10, 2025

Celebrating STEM Day: Investing in America’s innovators

November 8, 2025

Putting patients first: Breaking down barriers to care

October 28, 2025

Direct purchase programs can lower costs for patients

October 20, 2025

PBMs say they want lower priced medicines, so why don’t they cover them?

October 7, 2025

Manufacturing U.S. jobs and breakthroughs

October 6, 2025

Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states

September 15, 2025

PBMs are hiding hurdles to essential care

August 20, 2025

New study: PBMs and commercial insurers are quietly blocking prescription access

July 30, 2025

North Carolina puts patients first with rebate pass-through law

July 29, 2025

PBMs, not patents, are blocking access to lower-cost medicines

July 23, 2025

Bringing to life the full story of biopharmaceutical innovation and investments

July 22, 2025

Medicare Part D plans initially denied medicines for more than 70% of patients in four chronic disease areas

June 16, 2025

New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines

May 21, 2025

How the 340B hospital markup program and PBMs drive up costs for U.S. patients

May 16, 2025

Foreign first pricing schemes don’t address why Americans pay more

May 15, 2025

The AHIP premium dollar corrected (again)

May 8, 2025

PBMs launch new ad campaign to block reforms

May 5, 2025

From sound to science: How IP powers innovation in music and hearing

April 25, 2025

When middlemen own it all, patients pay the price

April 10, 2025

3 myths critics get wrong about intellectual property

March 28, 2025

New report finds more abuse of 340B program by hospitals and drug middlemen

March 24, 2025

A closer look at how health care consolidation drives up patient costs, creates barriers to care

March 17, 2025

Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change

March 13, 2025

Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation

March 12, 2025

Congress Keeps PBMs in the Hot Seat

March 6, 2025

New research: Industry sponsored clinical trials contribute billions to state economies

March 6, 2025

Wrapping up the J.P. Morgan Healthcare Conference

January 16, 2025

FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs

January 14, 2025

PhRMA CEOs Tee Up Next Week's Health Care Conference

January 11, 2025

New study: Entities that don’t make medicines get half of what is spent on those medicines

January 7, 2025

Recognizing the value of disease prevention with Dr. Len Friedland from GSK

December 12, 2024

Congratulations to our 2024 Working for Cures Employee Champions

December 11, 2024

Three things to know about 340B contract pharmacies

November 12, 2024

The PBM industry's desperate attempt to stop reform

November 12, 2024

PhRMA launches new ad calling for Congress to make sure savings go to patients, not PBMs

November 11, 2024

ICYMI: Grounding policy reforms in real lived patient experiences is key to improving outcomes

October 31, 2024

New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election

October 30, 2024

Guest Post: My health care vote

October 29, 2024

Insurers continue shifting more costs on to patients

October 28, 2024

Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey

October 28, 2024

ICYMI: The powerful companies driving local drugstores out of business

October 25, 2024

The importance of partnership: A conversation with Takeda

October 10, 2024

Hispanic Heritage Month: Fighting for Hispanic patients

October 7, 2024

PBMs and insurers off the hook: Sen. Sanders’ selective hearing on drug costs

September 24, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

Key voter insights two months from Election Day

September 10, 2024

Patient priorities in the 2024 election

September 10, 2024

Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers

August 1, 2024

Voters across all 50 states want state policymakers to focus on health insurance and PBM practices

July 30, 2024

WTAS: Voters voice concerns about PBM abuses, call on policymakers to act

July 19, 2024

PhRMA launches new ad in campaign exposing ways middlemen drive up costs

July 17, 2024

FTC report confirms PBMs profit at the expense of patients

July 10, 2024

New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices

July 9, 2024

The future of oncology R&D lies in policymakers’ hands

July 8, 2024

ICYMI: Hidden markups at mail-order pharmacies increase costs for employers

July 2, 2024

More than 60 researchers advocate on Capitol Hill

July 1, 2024

Alzheimer's & Brain Awareness Month: A conversation with Biogen

June 27, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eisai

June 24, 2024

ICYMI: What patients care about this election year

June 24, 2024

ICYMI: The Opaque Industry Secretly Inflating Prices for Prescription Drugs

June 21, 2024

Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company

June 20, 2024

ICYMI: Health care policy should be driven by patients, not politics

June 10, 2024

PhRMA Warns Federal Agencies: Consolidation and vertical integration among insurers, PBMs, and hospitals threaten patients

June 5, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

Ongoing federal probes shed light on PBM and insurer practices

May 20, 2024

Biopharmaceutical industry supports jobs and drives economic growth across the United States

May 16, 2024

WTAS: The consequences of consolidation and vertical integration

May 6, 2024

Insurance data: PBM reform has no material impact on premiums

April 24, 2024

New study finds insurers and PBMs increasing access restrictions in Medicare Part D

April 16, 2024

3 Takeaways from POLITICO’s Health Care Summit

April 3, 2024

PBMs using 340B program to drive profits at patients’ expense

March 28, 2024

Four years later, Maryland board still hasn’t delivered for patients

February 12, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

How the 340B program became a PBM giveaway

December 11, 2023

Congratulations to our 2023 Working for Cures Employee Champions

December 6, 2023

ICYMI: When middlemen get in the way, it’s the patients who lose

December 5, 2023

Get the facts on PCMA’s newest attempt to avoid accountability

December 4, 2023

Watch: Putting patients front and center for World AIDS Day

November 30, 2023

Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation

November 29, 2023

ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails

November 15, 2023

New Report: 1,600 cancer treatments and vaccines in clinical development

November 9, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

One year to Election Day: Four voter priorities to watch

November 6, 2023

ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report

October 25, 2023

New poll shows strong bipartisan support for PBM reform

October 20, 2023

4 truths about state government price setting

October 10, 2023

ICYMI: Government watchdog report finds patients in Medicare Part D paid billions more for medicines than insurers and PBMs

September 28, 2023

New analysis shows PBMs use fees as a profit center

September 18, 2023

It’s PBMs, not patents, blocking competition 

September 14, 2023

The Biden Administration has failed to advance an inclusive, worker-centered trade agenda

September 5, 2023

New PhRMA ad exposes yet another way PBMs get between patients and their medicines

September 5, 2023

Watch: New video series spotlights advances in biopharmaceutical science

August 24, 2023

Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation

July 26, 2023

Three things to know from the latest Patient Experience Survey

July 20, 2023

New report shows high-impact R&D happens after cancer medicines are first approved

July 10, 2023

More than 60 researchers ask Congress to support innovation

June 26, 2023

Biopharmaceutical science powered by PRIDE

June 16, 2023

ICYMI: PBM exec admits choosing profits over patients

June 2, 2023

Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics

May 30, 2023

Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth

May 18, 2023

Insulin: Key Facts on Access & Affordability

May 10, 2023

4 key facts on medicine prices and spending

May 9, 2023

4 Things to know about PhRMA’s new 50-state poll

May 4, 2023

New PhRMA ad campaign sheds light on PBM abuses

May 1, 2023

World IP Day 2023: Celebrating women leaders in innovation

April 26, 2023

Three facts about health care spending

April 25, 2023

AHIP’s latest misinformation campaign & what it’s trying to hide

April 24, 2023

ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability

April 7, 2023

States can support access to medicine as COVID-19 Public Health Emergency ends

April 5, 2023

Arkansas puts patients first with new share the savings law

April 4, 2023

Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care

March 29, 2023

U.S. biopharmaceutical exports support jobs, innovation

March 20, 2023

What we’ve learned from three years of fighting COVID-19

March 20, 2023

Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions

March 2, 2023

Holding pharmacy benefit managers accountable

February 23, 2023

Stopping pharmacy benefit managers from “gaming the system”

February 22, 2023

Senate hearing to examine bipartisan reforms to rein in middlemen

February 16, 2023

Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines

January 31, 2023

WTAS: Inflation Reduction Act already impacting R&D decisions

January 17, 2023

ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress

December 9, 2022

In their own words: Financial barriers exacerbate access challenges for insured Americans

December 8, 2022

Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit

December 8, 2022

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

December 1, 2022

New data show how insurers and middlemen shift Rx costs onto patients

November 16, 2022

Congratulations to our 2022 Working for Cures Employee Champions

November 10, 2022

In their own words: Insured Americans struggle to navigate complex coverage

October 26, 2022

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

October 13, 2022

New comments outline ways to protect patients from health plans and PBMs who profit from patient assistance

October 7, 2022

Navigating the patient experience: Burdens and barriers standing between patients and their care

September 12, 2022

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

August 16, 2022

Insulin and reconciliation

August 15, 2022

An open letter to Congress: Stand with patients and future cures

August 4, 2022

The Senate’s latest price setting proposal will undermine U.S. economic growth

August 3, 2022

ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill

July 29, 2022

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

July 18, 2022

Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US

July 14, 2022

Patients win as West Virginia implements first-in-nation share the savings policy

July 8, 2022

3 things voters are concerned about when it comes to their health care coverage

July 7, 2022

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

July 7, 2022

Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines

June 16, 2022

Biopharmaceutical researchers to discuss the value of R&D with Congress

June 9, 2022

New poll shows voters sounding the alarm on health insurance companies and PBMs

June 6, 2022

PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients

May 31, 2022

A conversation with Barry Greene, CEO of Sage Therapeutics

May 4, 2022

Stephanie Dyson of BMS on reducing health disparities

April 27, 2022

Biopharmaceutical industry drives economic growth in all 50 states

March 14, 2022

Guest post: Joining forces to combat the COVID-19 mental health crisis

February 17, 2022

Government price setting won’t stop insurers from shifting costs to patients

February 2, 2022

Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry

September 28, 2021

Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda

September 27, 2021

Industry leaders discuss the impact of the drug pricing debate

September 23, 2021

PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020

July 22, 2021

Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery

July 2, 2021

Watch: Building trust and enhancing clinical trial diversity

June 24, 2021

Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US

June 23, 2021

Researchers to shine light on biopharmaceutical R&D with policymakers

June 15, 2021

Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive

March 5, 2021

Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL

February 24, 2021

Beyond output and employment: The impact of America’s biopharmaceutical industry

February 11, 2021

Preserving U.S. innovation worldwide is more important than ever

January 29, 2021

Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen

January 28, 2021

New insulin report highlights how incentives benefit middlemen, harm patients

January 22, 2021

Key facts: The final rebate rule will be a positive change for patients

January 19, 2021

American biopharmaceutical manufacturing: Fueling economic growth now and for years to come

December 21, 2020

Report highlights biopharmaceutical industry’s commitment to D&I

December 17, 2020

Guest Post: Bringing our best to the fight against COVID-19

December 3, 2020

An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb

November 18, 2020